CoChat

Ex vivo human placental transfer of the peptides pramlintide and exenatide (synthetic exendin-4)

Open access
Hiles, Richard A, Bawdon, Roger E, Petrella, Ezio M · 2003 · Human & Experimental Toxicology

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

Two peptides, pramlintide (37 amino acids), an analog of human amylin, and exenatide, synthetic exendin-4 (39 amino acids), are both in late-stage clinical development as potential new treatments for people with diabetes. Both are potential long-term treatments, and there is the likelihood that some women will become pregnant while using one of these peptide therapies. Therefore, it was important to evaluate the potential for each peptide to cross the placental barrier and thereby result in exposure to the fetus. This was examined using ex vivo perfusions of human placentas. The fetal and maternal side of a cotyledon were cannulated and perfused first with buffer, and then with radioactive antipyrine in order to establish the integrity of the system and the perfusion constants. Either pramlintide or exenatide was then added to each acceptable cotyledon perfusate on the maternal side. Each peptide was evaluated at an initial concentration near the therapeutic plasma concentration and at approximately 10-50 times that concentration in each of the three cotyledons. Maternal and fetal perfusate samples were assayed for peptide concentrations using an immunoassay. The ratio of fetal-to-maternal peptide concentrations during equilibrium perfusion were extremely low (pramlintide ≤ 0.006, exenatide 5 ≤ 0.017). These data demonstrate negligible passage of either peptide across the placental barrier. It is, therefore, likely that maternal use of either peptide during gestation will result in negligible exposure to the fetus.

Overview

Integrity signals

Registry

Crossref · 10.1191/0960327103ht402oa

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 5 references

Research works printed but not linked: 2

  1. Keller JM, 1968, Obstet Gynecol, 32, 77
  2. Spellacy WN, 1976, Obstet Gynecol, 47, 291

Cited by

See all 46

Metadata

Authors
Hiles, R. A., Bawdon, R. E., & Petrella, E. M.
Affiliations
  • Amylin Pharmaceuticals, Inc., San Diego, CA, USA; 9373 Towne Centre Drive, San Diego, CA 92121, USA
  • The University of Texas Southwestern Medical Center (US)
  • Amylin Pharmaceuticals, Inc., San Diego, CA, USA
Corresponding author
Hiles, Richard A
Venue
Human & Experimental Toxicology
Published
2003-12
Volume
22
Issue
12
Pages
623-628
ISSN
  • 0960-3271 (ISSN-L)
  • 1477-0903
OpenAlex
W1991138106
Cited by
46
References
5
Citations by year
2026: 7 · 2025: 6 · 2024: 1 · 2023: 4 · 2022: 3 · 2019: 1 · 2018: 1 · 2017: 1 · 2015: 1 · 2014: 2 · 2012: 1
FWCI
2.37
Type
journal article
Language
en
Open access
Licence
journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations
  • Human & Experimental Toxicology (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
  • Health Sciences › Medicine › Obstetrics and Gynecology › Gestational Diabetes Research and Management
  • Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Pharmacological Effects and Toxicity Studies
Keywords
pramlintide, exenatide, exendin-4, amylin analogues, placental transfer, placental barrier, prenatal exposure, diabetes treatment, pregnancy, ex vivo placental perfusion
MeSH terms
Exenatide, Amyloid, Catheterization, Drug Evaluation, Preclinical, Female, Humans, Hypoglycemic Agents, Insulin, Maternal-Fetal Exchange, Metabolic Clearance Rate, Peptides, Perfusion, Placenta, Pregnancy, Venoms, Placental Circulation, Islet Amyloid Polypeptide

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Ex vivo human placental transfer of the peptides pramlintide and exenatide (synthetic exendin-4). https://app.cochat.ai/papers/10.1191/0960327103ht402oa
The paper
Hiles, R. A., Bawdon, R. E., & Petrella, E. M. (2003). Ex vivo human placental transfer of the peptides pramlintide and exenatide (synthetic exendin-4). Human & Experimental Toxicology. https://doi.org/10.1191/0960327103ht402oa

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.